-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

632.O1.6 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Mechanisms of resistance and expanded therapies

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Clinical Trials, Biological therapies, Epidemiology, Workforce, CML, Diversity, Equity, Inclusion, and Accessibility (DEI/DEIA) , Chronic Myeloid Malignancies, Diseases, Therapies, Myeloid Malignancies, Biological Processes
Saturday, December 11, 2021: 4:00 PM-5:30 PM
B304-B305, Level 3, Building B (Georgia World Congress Center)
Moderators:
Michael J. Mauro, MD, Memorial Sloan Kettering Cancer Center and Susan Branford, PhD, SA Pathology
Disclosures:
Mauro: Novartis: Consultancy, Research Funding; Takeda: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding; Pfizer: Consultancy; Sun Pharma / SPARC: Research Funding. Branford: Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Cepheid: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Qiagen: Honoraria, Membership on an entity's Board of Directors or advisory committees.
Chronic Myeloid Leukemia: Clinical and Epidemiological: Mechanisms of resistance and expanded therapies
4:00 PM

Michael W. Deininger, MD, PhD1, Jane F Apperley, FRCP, FRCPath, MB 2, Christopher Kevin Arthur, MBBS, FRACP, FRCPA3, Charles Chuah4, Andreas Hochhaus, MD5, Hugues De Lavallade6*, Jeffrey H. Lipton, MD, PhD7, Elza Lomaia, MD, PhD8*, James K McCloskey, MD9, Lori J. Maness, MD10, Michael J. Mauro, MD11, Beatriz Moiraghi, MD12*, Carolina Pavlovsky13*, Gianantonio Rosti14*, Philippe Rousselot15*, Soledad S. Undurraga, MD16, Vickie Lu, PhD17*, Alexander Vorog, MD17* and Jorge E. Cortes, MD18

1Division of Hematology and Hematologic Malignancies, University of Wisconsin Milwaukee, Milwaukee, WI
2Imperial College London, London, United Kingdom
3Department of Haematology, Royal North Shore Hospital, Sydney, NSW, Australia
4Singapore General Hospital, Duke-NUS Medical School, Singapore, Singapore
5Univerisitätsklinikum Jena, Jena, Germany
6King's College Hospital NHS Foundation, London, United Kingdom
7Hans Messner Allogeneic Blood and Marrow Transplant Unit, Princess Margaret Cancer Centre, Toronto, Canada
8Almazov National Medical Research Centre, St. Petersburg, Russian Federation
9Division of Leukemia, John Thuerer Cancer Center at Hackensack University Medical Center, Hackensack, NJ
10Division of Hematology & Oncology, Department of Internal Medicine, University of Nebraska Medical Center- Fred and Pamela Buffett Cancer Center, Omaha, NE
11Memorial Sloan-Kettering Cancer Center, New York, NY
12Hospital Jose Maria Ramos Mejia, Buenos Aires, Argentina
13Fundaleu, Buenos Aires, Argentina
14IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
15Centre Hospitalier de Versailles University de Versailles Saint-Quentin-en-Yvelines, Paris, France
16Hospital Del Salvador, Santiago, CHL
17Takeda Development Center Americas, Inc., Lexington, MA
18Georgia Cancer Center Augusta University, Augusta, GA

4:15 PM

Xiaoshuai Zhang1*, Zongru Li2*, Yazhen Qin3*, Robert Peter Gale4,5, Xiaojun Huang6 and Qian Jiang, MD7

1Peking University People's Hospital, Beijing, China
2Peking University Institute of Hematology, Peking University People’s Hospital, Beijing, China
3Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematology Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
4Haematology Research Center, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK, London, United Kingdom
5Centre for Haematology Research, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom
6Peking University People’s Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Collaborative Innovation Center of Hematology, Peking University, Beijing, China
7Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, People’s Republic of China, Beijing, China

4:30 PM

Jorge E. Cortes, MD1, Tapan Saikia, MD2, Dong-Wook Kim, M.D., Ph.D.3,4, Yesid Alvarado, MD5, Franck E. Nicolini, MD, PhD6, Krishnakumar Rathnam, MD, DM7*, Navin Khattry, MD, DM8*, Jane F Apperley, FRCP, FRCPath, MB 9, Michael W. Deininger, MD, PhD10,11, Hugues de Lavallade, MD, PhD12*, Aude Charbonnier, MD13*, Nikki Granacher, MD14*, Carlo Gambacorti-Passerini, MD15, Alessandro Lucchesi, MD16*, Michael J. Mauro, MD17, Peter Vandenberghe, MD, PhD18, Gregor Verhoef, MD, PhD18*, Andrew R. Whiteley, MD19, Arijit Nag, MD, DM20*, Vivek S Radhakrishnan, MD, DM, MSc20, Shashikant Apte, MD, FRCPA21, Siu-Long Yao, MD22, Sandeep Inamdar, MBBS23*, Jayasree Sreenivasan, MSc23*, Ruchika Irene Dillu, MD23* and Geetanjali Chimote, MD, PhD23*

1Georgia Cancer Center Augusta University, Augusta, GA
2Prince Aly Khan Hospital, Mumbai, India
3Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
4Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
5Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
6Hematology department, Centre Léon Bérard, Lyon, France
7Lake Area,Melur Main Rd, Meenakshi Mission Hospital and Research Centre, Tamil Nadu, India
8BMT unit, Department of Medical oncology, ACTREC., Tata Memorial Centre, Navi Mumbai, India
9Centre for Haematology, Department of Medicine, Hammersmith Hospital, Imperial College, London, ENG, United Kingdom
10Division of Hematology and Hematologic Malignancies, University of Wisconsin Milwaukee, Milwaukee, WI
11Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT
12Department of Haematological Medicine, Kings College Hospital, NHS Foundation Trust, London, United Kingdom
13Departement d'Hematologie, Institut Paoli Calmettes, Marseille, France
14Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium
15Dept of Medicine and Surgery, University of Milano Bicocca, Monza, MB, Italy
16Hematology Unit,, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), FC, Italy
17Myeloproliferative Neoplasms Program, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY
18Department of Hematology, UZ Leuven, Leuven, Belgium
19Baylor University Medical Center, Dallas, TX
20Clinical Hematology Oncology & HCT, Tata Medical Center, Kolkata, India
21Pune’s Sahyadri Hospital, Maharashtra, India
22Sun Pharmaceutical Industries, Inc., Princeton, NJ
23Sun Pharma Advanced Research Company Ltd, Mumbai, India

4:45 PM

Michael J. Mauro, MD1, Yosuke Minami, MD, PhD2, Delphine Rea, MD, PhD3, Andreas Hochhaus, MD4, Elza Lomaia, MD, PhD5*, Sergey Voloshin, MD, PhD6*, Anna G. Turkina, Prof., MD7, Dong-Wook Kim, M.D., Ph.D.8, Jane F Apperley, FRCP, FRCPath, MB 9, Jorge E. Cortes, MD10, Andre N.R. Abdo, MD11*, Laura Fogliatto12, Dennis Dong Hwan Kim, MD, PhD13*, Philipp D le Coutre, MD14, Susanne Saussele, MD 15, Mario Annunziata, MD16*, Timothy P. Hughes, MD, MBBS, FRACP, FRCPA17, Naeem A. Chaudhri, MD18, Lynette C.Y. Chee, MBBS, PhD, FRACP, FRCPA19, Valentín Garcia Gutierrez, MD, PhD20, Koji Sasaki, MD21, Shruti Kapoor22*, Alex Allepuz, MD, MPH23*, Sarah Quenet24*, Véronique Bédoucha24* and Carla Boquimpani, MD25*

1Myeloproliferative Neoplasms Program, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY
2Department of Hematology, National Cancer Center Hospital East, Kashiwa, Japan
3Hopital Saint Louis, Paris, France
4Department of Internal Medicine II, Jena University Hospital, Jena, Germany
5Almazov National Medical Research Centre, St. Petersburg, Russian Federation
6Russian Research Institute of Hematology and Transfusiology, Saint Petersburg, Russian Federation
7National Research Center for Hematology, Moscow, Russian Federation
8Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
9Centre for Haematology, Imperial College, London, United Kingdom
10Georgia Cancer Center Augusta University, Augusta, GA
11Instituto do Câncerdo Estado de São Paulo (ICESPSP), São Paulo, Brazil
12Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
13Hans Messner Allogeneic Blood and Marrow Transplant Unit, Princess Margaret Cancer Centre, Toronto, Canada
14Charité – Universitätsmedizin Berlin, Berlin, Berlin, Germany
15III. Medizinische Klinik, Universitätsmedizin Mannheim, Universität Heidelberg, Mannheim, Germany
16Hematology Unit, Azienda Ospedaliera Cardarelli, Naples, Italy
17Precision Medicine Theme, South Australian Health and Medical Research Institute SAHMRI, Adelaide, SA, Australia
18Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
19Department of Clinical Haematology and Bone Marrow Transplant Service, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia
20Hematology Service, Hospital Universitario Ramón y Cajal, Madrid, Spain
21Department of Leukemia, MD Anderson Cancer Center, Houston, TX
22Novartis Pharmaceuticals Corporation, East Hanover, NJ
23Novartis Pharma AG, Basel, NJ, Switzerland
24Novartis Pharma AG, Basel, Switzerland
25HEMORIO, State Institute of Hematology Arthur de Siquiera Cavalcanti, Rio de Janeiro, Brazil

5:00 PM

Jiang Qian, MD1, Dayu Shi2*, Zongru Li2*, Yazhen Qin2*, Ting Zhao2*, Bingcheng Liu3*, Zi Chen4,5*, Qian Niu4,5*, Lichuang Men4,5*, Hengbang Wang4,6*, Dajun Yang4,7*, Yifan Zhai4,5,8 and Xiaojun Huang9

1Peking University Institute of Hematology, Peking University People's Hospital, Beijing, Beijing, China
2Peking University Institute of Hematology, Peking University People’s Hospital, Beijing, China
3Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
4Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China
5Guangzhou Healthquest Pharma Co. Ltd., Guangzhou, China
6HealthQuest Pharma Inc., Guangzhou, China
7Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Guangzhou, China
8Ascentage Pharma Group Inc., Rockville, MD
9Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, 2019RU029, Beijing China, Beijing, China

5:15 PM

Mhairi Copland, PhD, MBBChir, FRCP, FRCPath1, Daniel Slade2*, Graham McIlroy2*, Gillian Horne1*, Jennifer Byrne3*, Kate Rothwell4*, Kristian Brock2*, Hugues De Lavallade5*, Charles Craddock, FRCP, FRCPath6, Richard Clark7*, Matthew Smith8*, Rachel Fletcher2*, Rebecca Bishop, BSc2*, Dragana Milojkovic9* and Christina Yap, BSc, MSc, PhD2,10*

1Paul O'Gorman Leukaemia Research Centre, University of Glasgow, Glasgow, United Kingdom
2Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom
3Centre for Clinical Haematology, Nottingham University, Nottingham, ENG, United Kingdom
4Department of Clinical Heamatology, Leeds Teaching Hospitals NHS Trust, Leeds, ENG, United Kingdom
5Department of Haemato-Oncology, King's College Hospital NHS Foundation, London, United Kingdom
6Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, ENG, United Kingdom
7Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom
8Department of Haemato-Oncology, St Bartholomew's Hospital, London, United Kingdom
9Centre for Haematology, Imperial College London, London, United Kingdom
10Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom

*signifies non-member of ASH